K Rebecca Fega1, Gregory A Abel2, Gabriela Motyckova2, Alexander E Sherman3, Daniel J DeAngelo2, David P Steensma2, Ilene Galinsky2, Martha Wadleigh2, Richard M Stone2, Jane A Driver4. 1. College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, United States. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. 3. College of Medicine, University of Cincinnati, Cincinnati, OH, United States. 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States; Geriatric Research Education and Clinical Center, VA Boston Medical Center, Boston, MA, United States; Division of Aging, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: jdriver@partners.org.
Abstract
OBJECTIVES: The International Prognostic Scoring System (IPSS) is commonly used to predict survival and assign treatment for the myelodysplastic syndromes (MDS). We explored whether self-reported and readily available non-hematologic predictors of survival add independent prognostic information to the IPSS. MATERIALS AND METHODS: Retrospective cohort study of consecutive MDS patients ≥age 65 who presented to Dana-Farber Cancer Institute between 2006 and 2011 and completed a baseline quality of life questionnaire. Questions corresponding to functional status and symptoms and extracted clinical-pathologic data from medical records. Kaplan-Meier and Cox proportional hazards models were used to estimate survival. RESULTS: One hundred fourteen patients consented and were available for analysis. Median age was 73 years, and the majority of patients were White, were male, and had a Charlson comorbidity score of <2. Few patients (24%) had an IPSS score consistent with lower-risk disease and the majority received chemotherapy. In addition to IPSS score and history of prior chemotherapy or radiation, significant univariate predictors of survival included low serum albumin, Charlson score, performance status, ability to take a long walk, and interference of physical symptoms in family life. The multivariate model that best predicted mortality included low serum albumin (HR=2.3; 95% CI: 1.06-5.14), therapy-related MDS (HR=2.1; 95% CI: 1.16-4.24), IPSS score (HR=1.7; 95% CI: 1.14-2.49), and ease taking a long walk (HR=0.44; 95% CI: 0.23-0.90). CONCLUSIONS: In this study of older adults with MDS, we found that low serum albumin and physical function added important prognostic information to the IPSS score. Self-reported physical function was more predictive than physician-assigned performance status. Published by Elsevier Ltd.
OBJECTIVES: The International Prognostic Scoring System (IPSS) is commonly used to predict survival and assign treatment for the myelodysplastic syndromes (MDS). We explored whether self-reported and readily available non-hematologic predictors of survival add independent prognostic information to the IPSS. MATERIALS AND METHODS: Retrospective cohort study of consecutive MDSpatients ≥age 65 who presented to Dana-Farber Cancer Institute between 2006 and 2011 and completed a baseline quality of life questionnaire. Questions corresponding to functional status and symptoms and extracted clinical-pathologic data from medical records. Kaplan-Meier and Cox proportional hazards models were used to estimate survival. RESULTS: One hundred fourteen patients consented and were available for analysis. Median age was 73 years, and the majority of patients were White, were male, and had a Charlson comorbidity score of <2. Few patients (24%) had an IPSS score consistent with lower-risk disease and the majority received chemotherapy. In addition to IPSS score and history of prior chemotherapy or radiation, significant univariate predictors of survival included low serum albumin, Charlson score, performance status, ability to take a long walk, and interference of physical symptoms in family life. The multivariate model that best predicted mortality included low serum albumin (HR=2.3; 95% CI: 1.06-5.14), therapy-related MDS (HR=2.1; 95% CI: 1.16-4.24), IPSS score (HR=1.7; 95% CI: 1.14-2.49), and ease taking a long walk (HR=0.44; 95% CI: 0.23-0.90). CONCLUSIONS: In this study of older adults with MDS, we found that low serum albumin and physical function added important prognostic information to the IPSS score. Self-reported physical function was more predictive than physician-assigned performance status. Published by Elsevier Ltd.
Authors: Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes Journal: J Natl Compr Canc Netw Date: 2012-02 Impact factor: 11.908
Authors: Barbara Deschler; Gabriele Ihorst; Uwe Platzbecker; Ulrich Germing; Eva März; Marcelo de Figuerido; Kurt Fritzsche; Peter Haas; Helmut R Salih; Aristoteles Giagounidis; Dominik Selleslag; Boris Labar; Theo de Witte; Pierre Wijermans; Michael Lübbert Journal: Haematologica Date: 2012-08-08 Impact factor: 9.941
Authors: Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase Journal: Blood Date: 2012-06-27 Impact factor: 22.113
Authors: Tanya M Wildes; Alexander P Ruwe; Chloe Fournier; Feng Gao; Kenneth R Carson; Jay F Piccirillo; Benjamin Tan; Graham A Colditz Journal: J Geriatr Oncol Date: 2013-07 Impact factor: 3.599
Authors: Lore Decoster; Cindy Kenis; Katrien Van Puyvelde; Johan Flamaing; Godelieve Conings; Jacques De Grève; Tony Mets; Koen Milisen; Jean Pierre Lobelle; Hans Wildiers Journal: J Geriatr Oncol Date: 2013-05-23 Impact factor: 3.599
Authors: Alexander E Sherman; Gabriela Motyckova; K Rebecca Fega; Daniel J Deangelo; Gregory A Abel; David Steensma; Martha Wadleigh; Richard M Stone; Jane A Driver Journal: Leuk Res Date: 2013-06-06 Impact factor: 3.156
Authors: Heidi D Klepin; Ann M Geiger; Janet A Tooze; Stephen B Kritchevsky; Jeff D Williamson; Timothy S Pardee; Leslie R Ellis; Bayard L Powell Journal: Blood Date: 2013-04-02 Impact factor: 22.113
Authors: Rafael Bejar; Kristen E Stevenson; Bennett A Caughey; Omar Abdel-Wahab; David P Steensma; Naomi Galili; Azra Raza; Hagop Kantarjian; Ross L Levine; Donna Neuberg; Guillermo Garcia-Manero; Benjamin L Ebert Journal: J Clin Oncol Date: 2012-08-06 Impact factor: 44.544
Authors: Reinhard Stauder; Ge Yu; Karin A Koinig; Tim Bagguley; Pierre Fenaux; Argiris Symeonidis; Guillermo Sanz; Jaroslav Cermak; Moshe Mittelman; Eva Hellström-Lindberg; Saskia Langemeijer; Mette Skov Holm; Krzysztof Mądry; Luca Malcovati; Aurelia Tatic; Ulrich Germing; Aleksandar Savic; Corine van Marrewijk; Agnès Guerci-Bresler; Elisa Luño; Jackie Droste; Fabio Efficace; Alex Smith; David Bowen; Theo de Witte Journal: Leukemia Date: 2018-03-06 Impact factor: 11.528